Cabotegravir in combination with rilpivirine is indicated for HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||15/06/2021|
|Rapid review completed||21/07/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that cabotegravir in combination with rilpivirine not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.